Le Lézard
Classified in: Health, Science and technology
Subjects: WOM, IMA

A Blood Test for the Detection of Breast Cancer: Syantra Receives CE Mark Approval for their Breast Cancer Test built on the Syantra DX Liquid Biopsy Platform


CALGARY, AB, April 18, 2023 /PRNewswire/ -- Syantra announced today that it has obtained CE marking for the Syantra DXTM Breast Cancer test. Syantra DXTM Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. The test evaluates gene expression patterns of 12 unique biomarkers through a custom qPCR process using proprietary software that includes machine learning-derived algorithms. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.  

Syantra Company Logo (CNW Group/Syantra Inc.)

 "Obtaining CE marking for the Syantra DXTM Breast Cancer test brings us one step closer to helping women across the globe detect breast cancer at earlier stages when it is most treatable," said Dr. Kristina Rinker, Syantra Co-founder and Chief Scientific Officer.

"Syantra's blood-based test may help improve breast cancer detection for women with high-risk of developing breast cancer, particularly young individuals with genetic predisposition and women with dense breasts or diverse ethnic backgrounds. For those women, standard screening mammogram may be inadequate and more sensitive tests are urgently needed," said Dr. Massimo Cristofanilli, Professor of Medicine, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.   Dr. Cristofanilli also serves as a paid scientific advisory board member for Syantra Inc.

About Syantra 

Syantra is a precision biotechnology company changing the way cancer is detected and treated. Its flagship product, Syantra DXTM Breast Cancer, is a minimally invasive and high-performance blood test for the detection of breast cancer, at the earliest stages.

Contact 

For more information about Syantra, and the Syantra DXTM Breast Cancer test, please visit: www.syantra.com

Social Media: LinkedIn, Twitter, Facebook, Instagram

Photo - https://mma.prnewswire.com/media/2052918/Syantra_Inc__A_Blood_Test_for_the_Detection_of_Breast_Cancer__Sy.jpg 


These press releases may also interest you

at 19:34
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...

at 16:48
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...

at 16:30
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...

at 15:40
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...

at 12:00
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...

at 12:00
SightMD Pennsylvania, a leading multi-specialty ophthalmology platform, is pleased to announce the acquisition of James Lewis, MD. Through this strategic partnership, Dr. Lewis's practice at 8380 Old York Rd Ste 110, Elkins Park, PA 19027 will expand...



News published on and distributed by: